IDEAYA Biosciences将于五月启动RTOR申请,新药上市申请预计2026年下半年完成

美股速递
Apr 30

IDEAYA Biosciences宣布,公司计划于今年五月启动实时肿瘤学审评(RTOR)提交程序。这一重要举措标志着其候选药物开发进入关键阶段。

根据最新时间表,IDEAYA Biosciences预计将在2026年下半年完成新药上市申请(NDA)的提交工作。该时间节点的确立为后续商业化进程奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10